We’re currently experiencing extremely high call volumes. We’re very sorry for any inconvenience this might cause.

If you need help with your account, please visit our Help Centre, or email us and we’ll get back to you as soon as we can. For more information and tips on managing your account online please visit www.hl.co.uk/coronavirus

We’re experiencing high call volumes, please check FAQs before calling.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Urovant Sciences Ltd (UROV) USD0.00001

Sell:$9.82 Buy:$9.97 Change: $0.18 (1.77%)
Market closed |  Prices as at close on 27 March 2020 | Switch to live prices |
Change: $0.18 (1.77%)
Market closed |  Prices as at close on 27 March 2020 | Switch to live prices |
Change: $0.18 (1.77%)
Market closed |  Prices as at close on 27 March 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for urologic conditions. Its product candidate, vibegron, is an oral, once-daily, small molecule beta-3 agonist. is focused on evaluating vibegron in its over 1,400 patients, pivotal phase-3 clinical trial for the treatment of overactive bladder (OAB). The Company’s subsidiaries include Urovant Sciences, Inc., Urovant Holdings Limited, and Urovant Sciences GmbH.

Contact details

5281 California Ave Ste 100
United States
+1 (949) 2266029

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$309.78 million
Shares in issue:
30.52 million
US dollar
NASDAQ Comb. Composite

Key personnel

  • Myrtle Potter
    Chairman of the Board
  • James Robinson
    Principal Executive Officer, Director
  • Ajay Bansal
    Chief Financial Officer, Senior Vice President - Business Development, Principal Financial Officer
  • Christine Ocampo
    Senior Vice President, Chief Accounting Officer, Principal Accounting Officer
  • Cornelia Haag-Molkenteller
    Chief Medical Officer of USI
  • Michael McFadden
    Chief Commercial Officer
  • Bryan Smith
    General Counsel - USI

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.